Literature DB >> 11948490

Enzymatic oxidation products of spermine induce greater cytotoxic effects on human multidrug-resistant colon carcinoma cells (LoVo) than on their wild-type counterparts.

Annarica Calcabrini1, Giuseppe Arancia, Manuela Marra, Pasqualina Crateri, Olivia Befani, Alessandro Martone, Enzo Agostinelli.   

Abstract

The occurrence of resistance to cytotoxic agents in tumor cells, associated with several phenotypic alterations, is one of the major obstacles to successful anticancer chemotherapy. A new strategy to overcome MDR of human cancer cells was studied, using BSAO, which generates cytotoxic products from spermine, H(2)O(2) and aldehyde(s). The involvement of these products in causing cytotoxicity was investigated in both drug-sensitive (LoVo WT) and drug-resistant (LoVo DX) colon adenocarcinoma cells. Evaluation of clonogenic cell survival showed that LoVo DX cells are more sensitive than LoVo WT cells. Fluorometric assay and treatments performed in the presence of catalase demonstrated that the cytotoxicity was due mainly to the presence of H(2)O(2). Cytotoxicity was eliminated in the presence of both catalase and ALDH. Transmission electron microscopic observations showed more pronounced mitochondrial modifications in drug-resistant than in drug-sensitive cells. Mitochondrial functionality studies performed by flow cytometry after JC-1 labeling revealed basal hyperpolarization of the mitochondrial membrane in LoVo DX cells. After treatment with BSAO and spermine, earlier and higher mitochondrial membrane depolarization was found in LoVo DX cells than in drug-sensitive cells. In addition, higher basal ROS production in LoVo DX cells than in drug-sensitive cells was detected by flow-cytometric analysis, suggesting increased mitochondrial activity in drug-resistant cells. Our results support the hypothesis that mitochondrial functionality affects the sensitivity of cells to the cytotoxic enzymatic oxidation products of spermine, which might be promising anticancer agents, mainly against drug-resistant tumor cells. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11948490     DOI: 10.1002/ijc.10310

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Hypusinated EIF5A as a feasible drug target for Advanced Medicinal Therapies in the treatment of pathogenic parasites and therapy-resistant tumors.

Authors:  Annette Kaiser; Enzo Agostinelli
Journal:  Amino Acids       Date:  2022-01-09       Impact factor: 3.520

2.  Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells.

Authors:  Paola Matarrese; Valeria Manganelli; Tina Garofalo; Antonella Tinari; Lucrezia Gambardella; Kenneth Ndebele; Roya Khosravi-Far; Maurizio Sorice; Mauro Degli Esposti; Walter Malorni
Journal:  Biochem J       Date:  2008-08-01       Impact factor: 3.857

Review 3.  Polyamine catabolism and oxidative damage.

Authors:  Tracy Murray Stewart; Tiffany T Dunston; Patrick M Woster; Robert A Casero
Journal:  J Biol Chem       Date:  2018-10-17       Impact factor: 5.157

4.  Catalytically active bovine serum amine oxidase bound to fluorescent and magnetically drivable nanoparticles.

Authors:  Giulietta Sinigaglia; Massimiliano Magro; Giovanni Miotto; Sara Cardillo; Enzo Agostinelli; Radek Zboril; Eris Bidollari; Fabio Vianello
Journal:  Int J Nanomedicine       Date:  2012-05-03

5.  Glutathione metabolism in Candida albicans resistant strains to fluconazole and micafungin.

Authors:  Bruno Maras; Letizia Angiolella; Giuseppina Mignogna; Elisabetta Vavala; Alberto Macone; Marisa Colone; Giuseppina Pitari; Annarita Stringaro; Silvestro Dupré; Anna Teresa Palamara
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

6.  Oxidative degradation of polyamines by serum supplement causes cytotoxicity on cultured cells.

Authors:  Linlin Wang; Ying Liu; Cui Qi; Luyao Shen; Junyan Wang; Xiangjun Liu; Nan Zhang; Tao Bing; Dihua Shangguan
Journal:  Sci Rep       Date:  2018-07-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.